Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 5948Pancreatic Neoplasms 3563Carcinoma, Hepatocellular 3273Stomach Neoplasms 3057Colonic Neoplasms 2328Rectal Neoplasms 2192Esophageal Neoplasms 1801Liver Neoplasms 1247Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 871Carcinoma, Non-Small-Cell Lung 794Lung Neoplasms 745Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 585Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 304Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

Oxaliplatin 2tislelizumab 1sintilimab 1donafenib 1Immunotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Carcinoma × Gastrointestinal × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

NCT04984980 2023-01-26

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Fudan University

Phase 2 Unknown
37 enrolled
Gastrointestinal

Biliary Tract Carcinoma

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Fudan University

Phase 1/2 Unknown
10 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡